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PPAR𝛼 agonist clofibrate reduces cholesterol and fatty acid concentrations in rodent liver by an inhibition of SREBP-dependent
gene expression. In present study we investigated the regulation mechanisms of the triglyceride- and cholesterol-lowering effect
of the PPAR𝛼 agonist clofibrate in broiler chickens. We observed that PPAR𝛼 agonist clofibrate decreases the mRNA and protein
levels of LXR𝛼 and the mRNA and both precursor and nuclear protein levels of SREBP1 and SREBP2 as well as the mRNA levels
of the SREBP1 (FASN and GPAM) and SREBP2 (HMGCR and LDLR) target genes in the liver of treated broiler chickens compared
to control group, whereas the mRNA level of INSIG2, which inhibits SREBP activation, was increased in the liver of treated broiler
chickens compared to control group. Taken together, the effects of PPAR𝛼 agonist clofibrate on lipid metabolism in liver of broiler
chickens involve inhibiting transcription and activation of SREBPs and SREBP-dependent lipogenic and cholesterologenic gene
expression, thereby resulting in a reduction of the triglyceride and cholesterol levels in liver of broiler chickens.
1. Introduction
The lipid metabolism in mammalian is regulated mainly
by transcription factors including peroxisome proliferator-
activated receptor alpha (PPAR𝛼), liver X receptor alpha
(LXR𝛼), and sterol regulatory element-binding proteins
(SREBPs) [1–6]. PPAR𝛼 is a ligand-activated transcription
factor known to regulate expression of numerous genes
involved in fatty acid uptake and oxidation, ketogenesis, glu-
coneogenesis, cholesterol catabolism, and lipoprotein
metabolism [7, 8]. Transcriptional regulation of genes by
PPAR𝛼 is mediated by forming a heterodimer with the
retinoid X receptor (RXR) and subsequent binding of
the PPAR𝛼/RXR heterodimer to peroxisome proliferator
response element (PPRE) presenting in the promoter of
target genes. Ligands of PPAR𝛼 are fatty acids and fatty acid
derivatives (eicosanoids) as well as a heterogenous group
of synthetic compounds including the fibrate class of lipid
lowering drugs (clofibrate, fenofibrate, bezafibrate, and
gemfibrozil) [7, 8]. The lipid-lowering mechanism of fibrates
involves activation of PPAR𝛼 in the liver leading to an
upregulation of genes involved in cellular fatty acid uptake,
carnitine-dependent mitochondrial fatty acid uptake, and
mitochondrial and peroxisomal 𝛽-oxidation and, thereby,
to an increased fatty acid catabolism and decreased triacyl-
glycerol concentrations in liver and blood [7, 8]. In addition,
it has been shown that activation of PPAR𝛼 by fibrates
and oxidized fatty acids decreases the expression of genes
involved in lipid synthesis and lipid uptake in the liver
[9–12] indicating that the lipid-lowering effect of fibrates also
involves reduction of lipid synthesis.
The LXR𝛼 is implicated in regulation of intracellular
cholesterol levels and lipogenesis in mammals [13–15]. LXR𝛼
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functions by forming obligate heterodimers with the retinoid
X receptor (RXR) and subsequently binds to LXR response
element (LXRE) within the promoters of the target genes,
thereby regulating gene expression [14]. It was reported that
fatty acidmetabolism in rat is regulated by cross-talk between
PPAR𝛼 and LXR𝛼, in which PPARs suppress SREBP1c
activation through inhibition of LXR signaling [16–18].
The SREBPs are transcription factors regulating the tran-
scription of genes related to lipid synthesis and uptake [5, 6,
19], from which the SREBP1c isoform preferentially activates
genes required for fatty acid and triacylglycerol synthesis like
fatty acid synthase (FASN) and glycerophosphate acyltrans-
ferase, and mitochondrial (GPAM) [1, 20], and the SREBP2
isoform stimulates mainly genes involved in cholesterol syn-
thesis and uptake such as 3-hydroxy-3-methylglutaryl CoA
reductase (HMGCR) and low-density lipoprotein receptor
(LDLR) [2, 19]. SREBPs are synthesized as inactive pre-
cursor proteins and form a complex with SREBP cleavage
activating protein (SCAP), which is initially bound to the
rough endoplasmic reticulum membrane by the insulin-
induced genes (INSIGs). Activation of SREBPs involves the
release of the SCAP-SREBP complex from INSIGs and its
translocation to the Golgi, where the N-terminus of SREBP is
cleaved by proteolysis and translocated to the nucleus where
it can bind to specific sterol response elements (SREs) in the
promoters of target genes, thereby activating their transcrip-
tion [5, 6].
It has been shown that feeding PPAR𝛼 activators to rats
or treatment of rat liver cells with PPAR𝛼 activators causes
an inhibition of SREBP1 and SREBP2 activation and an
upregulation of INSIG1 and INSIG2 [9–11] suggesting that the
decreased expression of genes involved in lipid synthesis and
lipid uptake in response to fibrates and oxidized fatty acids is
mediated by PPAR𝛼.Themajor sites of fatty acid synthesis are
adipose tissue and the liver in animals. However, the relative
contribution for the whole body lipogenesis is highly variable
among species. In the pigs and ruminants adipose tissue is
the main lipogenic organ with minor contribution from the
liver, while in the rodents and rabbits both liver and adipose
tissue are important for lipogenesis [20, 21]. However in avian
species the liver is the predominant lipogenic site [20, 22–
24] because its lipogenesis capacity markedly exceeds that
of adipose tissue [25], indicating that an inhibitory effect of
fibrates on hepatic lipid synthesis has a greater impact on lipid
concentrations in birds than in other species. To our knowl-
edge, however, it has not been shown whether fibrates inhibit
the activation of SREBPs in the liver of birds. Therefore, the
aim of the present study was to investigate the effect of the
PPAR𝛼 agonist clofibrate on activation of hepatic SREBPs in
birds by determining both expression levels of mRNA and
protein of LXR𝛼 and SREBP1/SREBP2 and mRNA levels of
the SREBP1 target genes FASN andGPAM and SREBP2 target
genes HMGCR and LDLR as well as the mRNA levels of
INSIG1 and INSIG2. For this end, we performed a feeding
experiment with broiler chickens that were fed either a
control diet or a diet supplemented with clofibrate for 4
weeks.
2. Material and Methods
2.1. Animals Treatment. All experimental procedures were
approved by the Shanxi Administration Office of Laboratory
Animals (2012011035-2). A total of 48 one-day-old Arber
Acres broiler chickens were used in the experiment. Until
the end of the second week, all broilers were fed with a
commercial starter diet (Nutrition R&DCenter of Institute of
Animal Husbandry and Veterinary Sciences, Shanxi Provin-
cial Academy of Agricultural Sciences) containing 13.3 MJ
metabolizable energy and 19.1% crude protein per kg diet. At
the beginning of the third week, the broiler chickens were
randomly assigned into two groups of 24 animals each. The
animals of both groups were kept in groups of 8 birds/group
in wire cages in a room with controlled temperature of 22–
24∘Con a 18 h light and 6 h dark cycle.The animals of the con-
trol groupwere fed a commercial grower diet (NutritionR&D
Center of Institute of Animal Husbandry and Veterinary Sci-
ences, Shanxi Provincial Academy of Agricultural Sciences),
whereas animals of the clofibrate groupwere fed the same diet
supplemented with 1 g clofibrate [ethyl 2-(4-chlorophenoxy)-
2-methylpropanoate] (TCI-Tokyo chemical Industry, Tokyo,
Japan) per kg diet. This dose was chosen based on a recent
study [26], in which a clofibrate dose of 1.5 g/kg diet was
used to treat 20-week-old laying hens for 4 weeks and caused
an activation of PPAR𝛼 in animal liver without toxic effects.
Considering health and growth of broiler chickens we chose
a clofibrate dose of 1 g/kg diet. For 1 kg diet 1 g clofibrate was
dissolved in 25mL sunflower oil and mixed very well with
the vitamin-mineral premix, subsequently with ration of rest.
The control animals received an equal volume of the vehicle.
The composition of the experimental grower diets is shown
in Table 1. Feed and water were supplied ad libitum during
the entire experiment. Body weight and feed intake were
recorded every week. Feed conversion ratio (FCR) was calcu-
lated by measurement of feed intake to body weight gain.
2.2. Sample Collection. After treatment for 4 weeks, all birds
were individually weighed and then killed. Liver was excised
and weighed. Aliquots of liver tissue for RNA and protein
isolation as well as lipid extraction were snap-frozen in liquid
nitrogen and stored at −80∘C.
2.3. Determination of Lipid Concentrations in the Liver. For
determination of triglyceride and total cholesterol concentra-
tions in the liver, liver lipids were extracted from pooled liver
tissue, with liver tissue from 3 animals contributing to each
pool (about 15–20mg from each animal for determination
of triglyceride, and 10–15mg for determination of total
cholesterol), using a mixture of n-hexane and isopropanol
(3 : 2, v/v) [27], and aliquots of the lipid extracts were dried
and dissolved in a small volume of Triton X-100 [28]. Con-
centrations of triglycerides and cholesterol were determined
using enzymatic reagent kits (Tissue triglyceride assay kit,
catalogue number E1013 and tissue total cholesterol assay kit,
catalogue number E1015, Applygen Technologies Co., Ltd.,
Beijing, China) following the manufacturer’s protocol.
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Fish meal 25 25
Wheat middlings 30 30
Soybean meal 44% 260 260
Sunflower oil 25 25
Limestone powder 10 10
Calcium hydrogen phosphate 14.8 14.8
Sodium chloride 2.5 2.5
Vitamin-mineral mix1 1.2 1.2
DL-methionine 1 1
Choline chloride 50% 0.5 0.5
Clofibrate — 1.0
Crude nutrients and energy content
Dry matter (%) 89.84 89.84
Metabolizable energy (MJ/kg) 13.3 13.3
Crude protein (%) 19.1 19.1
Crude fat (%) 5.5 5.5
Linoleic acid (%) 2.0 2.0
Crude fibre (%) 2.6 2.6
Calcium (%) 0.98 0.98
Available phosphorus (%) 0.49 0.49
1The vitamin-mineral mix provided per kg of diet: 3.3mg retinol, 0.033mg
cholecalciferol, 13.34mg D-𝛼-tocopheryl acetate, 0.5mg menadione, 2.2mg
thiamine, 6.6mg riboflavin, 5.5mg pyridoxine, 0.01mg cobalamin, 13.5mg
pantothenate, 0.2mg biotin, 1.0mg folic acid, 44mg nicotinic acid, 350mg
magnesium, 9.6mg copper, 100mg iron, 108mg manganese, 88mg zinc,
0.23mg selenium, and 0.4mg iodine.
2.4. Total RNA Isolation and Quantitative Real-Time
PCR Analysis (qPCR)
2.4.1. RNA Isolation. For RNA isolation andReal-Time qPCR
analysis we used the same protocol described by Keller
et al. [29] with minor modifications. Briefly, total RNA
was isolated from 20–30mg of frozen liver tissue using
Trizol Reagent (Shanghai Invitrogen Biotechnology Co., Ltd.,
China) according to the manufacturer’s protocol. RNA con-
centration and purity were estimated by measuring the opti-
cal density (OD) at 260 and 280 nm, respectively, using Nan-
oDrop Spectrophotometer ND-1000 (Thermo Fisher Bio-
chemical Product (Beijing) Co., Ltd., China). RNA used for
RT-PCR had an A260/A280 ratio 1.94 ± 0.05. RNA integrity
and qualitywere evaluated by 1.2% agarose gel electrophoresis
and all samples had intact bands corresponding to the 18S
and 28S ribosomal RNA subunits (Supplementary Figure 1 in
Supplementary Material available online at http://dx.doi.org/
10.1155/2015/347245).
2.4.2. cDNA Synthesis. The first-strand cDNA was synthe-
sized using 1.2 𝜇g of total RNA, 1 𝜇L dT18 (100 pmol/𝜇L)
primer (TaKaRa, Dalian, China), 1.25 𝜇L dNTP mix (10mM)
(Thermo Fisher Biochemical Product (Beijing) Co., Ltd.,
China), 5𝜇L buffer (5x reaction buffer), 0.3 𝜇L M-MuLV
Reverse Transcriptase (200 units/𝜇L) (Thermo Fisher Bio-
chemical Product (Beijing) Co., Ltd., China), and x 𝜇L DEPC
treated water tomake a 25 𝜇L final reaction volume and incu-
bated at 42∘C for 60min, following a final inactivating step at
60∘C for 10min in Bio-Rad C1000 Touch thermal cycler PCR
(Bio-Rad Laboratories, (Beijing) Co., Ltd., China).
2.4.3. Primer Design and Test of Amplification Efficiency.
Gene-specific primer pairs (Table 2) synthesized by TaKaRa
(Dalian, China) were designed using Clone Manager Pro-
fessional software 9.2. All primer pairs were designed to
have melting temperature of about 60∘C. The primer pairs,
if possible, were designed to be located in different exons. To
estimate amplification efficiency of primer, a cDNApool from
each sample was made and serial dilution for standard curve
for each primer was prepared. The qRT-PCR reactions were
carried out in a 0.1mL tube (Qiagen, Germany, cat. number
981103) each with a total volume of 20𝜇L and in a Rotor-
Gene Q 2plex HRM System (Qiagen, Germany, cat. number
9001630). Each PCR mixture contained 2𝜇L cDNA, 0.4 𝜇L
each of 10 𝜇M forward and reverse primers, 10𝜇L Maxima
SYBR Green qPCR Master Mix (Thermo Fisher Biochemical
Product (Beijing) Co., Ltd., China), and 7.2 𝜇L DNase/RNase
free water. The qRT-PCR protocol was as follows: 3min at
95∘C, followed by 30–45 cycles, a two-step PCR consisting of
5 sec at 95∘C for denaturation and 20 sec at 60∘C for annealing
and extension. Subsequently, melting curve analysis was per-
formed from50∘C to 95∘C to check for the presence of a single
PCR product or contamination during the PCR reaction. In
addition, the amplifications of specific PCR products were
confirmed by performing a 2% agarose gel electrophoresis
stained with GelRed Nucleic Acid Gel Stain (Biotium, (Bei-
jing) Co., Ltd., China). After PCR running Ct (threshold
cycle) values were collected by Rotorgene Software 5.0 (Qia-
gen, Germany) with an automated analysis and exported
in Excel files. The correlation coefficient (𝑅2) and the slops
were calculated using standard curve. The slop was used
to determine the efficiency of each primer (Supplementary
Table 1).
2.4.4. Selection of Candidate Reference Genes. Reference
genes were chosen from some published literatures in rat,
pig, or cow [29–31]. Reference gene stability and the nor-
malization factor were determined by performing GeNorm
analysis described by Keller et al. [29] and Vandesompele et
al. [32]. The candidate gene possessing 𝑀-value below 1.5
is considered as stably expressed gene. The optimal number
of reference genes is determined by pairwise variation (𝑉)
analysis with a𝑉-value below 0.15 [33]. After PCR running Ct
values of reference genes were collected and then exported in
Excel files. Ct values were transformed to relative quantifica-
tion data using the equation 2ΔCt, where ΔCt = (minCt − Ct),
where minCt is the lowest Ct value over a range of samples,
and Ct is sample Ct. The sample with minimum expression
was used as the calibrator with a set value of 1. Subsequently,
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Table 2: Characteristics and performance data of the primers used for reference gene-stability measure𝑀 and quantitative real-time PCR
analysis.
Gene name Primer sequence (forward, reverse) Product size (bp) NCBI GenBank
Reference genes
ATP5B GGTGTGCAGAAGATCCTTCA, GATCTGCTTGAAGCCCTTGA 216 NM 001031391
TOP1 GCATCATGCCAGAAGACATC, CTTGAGCTAGGGTTCAACATT 175 NM 205110
MDH1 GCATGGAGAGGAAGGATTTG, GAAGTCACACCAAGCTTCAG 241 NM 001006395
RPL13 GTTCGTGCTGGCAGAGGAT, GACAGCTGAGTTGCCATCTT 245 NM 204999
YWHAZ TGTGGAGCAATCACAACAGG, GTTGTCTCTCAGTAACTGCAT 250 NM 001031343
GAPDH CACTTCAAGGGCACTGTCAA, CTCATGGTTGACACCCATCA 252 NM 204305
Target genes
PPAR𝛼 GGAGTTTAAGTGACCGCTCT, CTGATCCATCAGATCCTGGA 230 NM 001001464
CPT1A ACTCTCCAGCACGTGAAAGA, CCTGCAGTAAGAGCTGCTAA 118 NM 001012898
SREBF1 ACCTGGCAGCCAAGGCAT, GACTCAGCCATGATGCTTCT 168 NM 204126
FASN CTCCTTGAAGGTGGTTTGCA, CCTCCATGTTTCCTGCTTTC 219 NM 205155
GPAM GTTGAGACAGCAGCAGTTTTT, CCTTCAATTATGCGATCGTAG 177 XM 421757
SREBF2 CATTCTGACCACAATGCCAG, GGTCCTTCAGCTCAATGATC 176 AJ414379
HMGCR GCTTAGCCTTTCTCCTTGCT, CCAGATTGTTTCCTGCAGCA 250 XM 422225
LDLR CACTCAGTGCCACCATTTGG, CTGCGACGGAACGTCCAAG 203 NM 204452
INSIG1 CCAACAATGTCCAGCTGTCC, CACCATTATATACAAGGAACTG 147 NM 001030966
INSIG2 GGATTTTGCCAACAATATCCAG,TGTAGACCAGAAGCTGTGACA, 149 NM 001031261
LXR𝛼 CCAAGATGCTGGGAAATGAAGC, ATATACATGTCCATCTCACAC 193 NM 204542
Sterol regulatory element binding transcription factors 1 and 2 (SREBF1 and SREBF2); peroxisome proliferator-activated receptor alpha (PPAR𝛼); carnitine
palmitoyltransferase 1A (CTP1A); fatty acid synthase (FASN); glycerol-3-phosphate acyltransferase, mitochondrial (GPAM); 3-hydroxy-3-methylglutaryl
CoA reductase (HMGCR), low-density lipoprotein receptor (LDLR); Liver X-Receptor alpha (LXR𝛼); insulin induced genes 1 and 2 (INSIG1 and INSIG2);
ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide (ATP5B); topoisomerase (DNA) I (TOP1); malate dehydrogenase 1, NAD
(soluble) (MDH1); ribosomal protein L13 (RPL13); tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (YWHAZ);
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
2
ΔCt results were used as input data for Microsoft excel-based
software geNorm and normalization factors were calculated
by the geNorm software. The 𝑀-value and 𝑉-value as well
as ranking reference genes for stability of expression were
reported as in the figure by geNorm output (Supplementary
Figures 2 and 3). Based on the𝑀-values and𝑉-values, out of
six tested potential reference genes including MDH1, RPL13,
GAPDH,YWHAZ,ATP5B, andTOP1, the five reference genes
MDH1, RPL13, GAPDH, YWHAZ, and ATP5B with 𝑀 <
1.5 and 𝑉5/𝑉6 = 0.154, which was near the proposed
cutoff value of 0.15, were used to calculate a gene expression
normalization factor for each sample.
2.4.5. Data Analysis. After PCR running the relative quan-
tification of target genes was performed using 2ΔCt method
described above and then normalized by the normalization
factor using geNorm. The qRT-PCR data for each gene prior
to statistical analysis were normalized to the control by divid-
ing each data point by the mean of the control group. This
resulted in a mean of 1 for the control and an expression ratio
for the treated group compared to the control group.
2.5. Immunoblot Analysis. Nuclear extracts were prepared
from 100mg pooled liver tissue, with liver tissue from 3
animals contributing to each pool (about 30–40mg from
each animal), using Nuclear Extract Kit (Active Motif,
(Shanghai) Co., Ltd., China) according to the manufacturer’s
protocol. Protein content was determined by the bicin-
choninic acid protein assay kit (TaKaRa, Dalian, China)
and BSA as standard. Proteins were separated by SDS-
PAGE and electrotransferred to nitrocellulose membranes
(Bio-Rad Laboratories, (Beijing) Co., Ltd., China). The blots
were incubated overnight at 4∘C with primary antibodies
against rabbit polyclonal SREBP1 (1 : 500, Santa Cruz, USA),
SREBP2 (1 : 500, Santa Cruz, USA), and LXR𝛼 (1 : 500, Affin-
ity Bioreagents, USA), as well as mouse monoclonal 𝛽-actin
(1 : 10.000, Abcam, Cambridge, UK) as internal control for
normalization. The membranes were washed and then incu-
bated with a horseradish peroxidase-conjugated secondary
anti-rabbit-IgG or anti-mouse IgG antibody (1 : 10.000 Santa
Cruz, USA) at room temperature. Afterward, blots were
developed using ECL Plus (Bio-Rad Laboratories, (Beijing)
Co., Ltd., China). Band intensities were evaluated densit-
ometrically using ChemiDoc MP Image Lab System and
Image Lab Software 5.1 according to the manufacturer’s
guideline (http://www.bio-rad.com/webroot/web/pdf/lsr/lit-
erature/10022469.pdf) (Bio-Rad Laboratories, (Beijing) Co.,
Ltd., China).
2.6. Statistics Analysis. Data were expressed as means± SEM
(standard error of mean). Statistical analysis was performed
using SAS 9.1.3 statistical software (SAS Institute, Inc., 2001).
Data of experiment were analyzed for normality of distri-
bution (Anderson-Darling test). Because all data showed
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Table 3: Concentrations of triglycerides and cholesterol in the liver
of broiler chickens fed diets without (control) or with 0.1% clofibrate
for 4 weeks.
Lipid Control Clofibrate
Triglycerides (𝜇mol/g) 74.6 ± 4.56 35.5 ± 2.83∗
Cholesterol (𝜇mol/g) 11.2 ± 0.40 7.5 ± 0.98∗
Values are means ± SEM, 𝑛 = 3 pools/group with each pool representing 3
animals.
∗Significantly different from control (𝑃 < 0.05).
a normal distribution, one-way ANOVA was applied to
evaluate the effect of treatment. Means of the treatment
(clofibrate group) were compared with the control group by
Student’s 𝑡-test. Significant difference was declared with a𝑃 <
0.05.
3. Results
3.1. Body Weights, Feed Intake, and Feed Conversion Ratio.
Feeding of the diet with clofibrate did not reduce perfor-
mance characteristics of broiler chickens. Initial body weight
of the experimental animals (IBWE) and final body weights
(FBW), average daily feed intake (ADF), and feed conversion
ratio (FCR) did not differ between the control group and the
clofibrate group (IBWE: 314 ± 10 versus 319 ± 11 g; FBW:
1946 ± 45 versus 1966 ± 43 g; ADF: 123 ± 2 versus 108 ± 2 g;
FCR: 1.93 ± 0.06 versus 2.06 ± 0.04; 𝑛 = 24/group).
3.2. Concentrations of Triglyceride and Cholesterol in the
Liver. The concentrations of triglyceride and cholesterol
were significantly lower in the liver of broiler chickens treated
with clofibrate than that of the control group (Table 3).
3.3. Relative mRNA Concentrations of PPAR𝛼 and the PPAR𝛼
Target Gene CPT1A in the Liver. To evaluate activation of
hepatic PPAR𝛼 by clofibrate, we determined the mRNA level
of the classical PPAR𝛼 target gene CPT1A in the liver. As
shown in Figure 1, the mRNA level of CPT1A in the liver was
about 35% greater in the clofibrate group than in the control
group (𝑃 < 0.05) indicating activation of hepatic PPAR𝛼
by clofibrate. The mRNA level of PPAR𝛼 in the liver did not
differ between broiler chickens of the control group and the
clofibrate group.
3.4. Relative mRNA Concentrations of SREBFs and Their
Target Genes in the Liver. To investigate whether activation
of hepatic PPAR𝛼 is accompanied by a reduced expression
of genes involved in lipid synthesis and uptake in the liver,
we determined mRNA levels of SREBFs and SREBP target
genes. As illustrated in Figure 2, mRNA levels of SREBF1
and SREBP1 target genes (FASN, GPAM) and SREBF2 and
SREBP2 target genes (HMGCR, LDLR) in the liver of broiler
chickens were approximately 20% to 50% less in the clofibrate
group than in the control group (𝑃 < 0.05).
3.5. Relative Protein Levels of Precursor and Nuclear SREBPs
in the Liver. In order to explain the reduced expression of
























Figure 1: mRNA level relative to control of PPAR𝛼 and its target
gene CPT1A in the liver of broiler chickens fed diets without
(control) or with 0.1% clofibrate for 4 weeks. Values are means ±
SEM, 𝑛 = 24/group.



























Figure 2: mRNA level relative to control of SREBF1, SREBF2, and
SREBP1 (FASN, GPAM) and SREBP2 (HMGCR, LDLR) target genes
in the liver of broiler chickens fed diets without (control) or with
0.1% clofibrate for 4 weeks. Values are means ± SEM, 𝑛 = 24/group.
chickens, we determined the protein levels of precursor and
the transcriptionally active nuclear SREBPs in the liver. In line
with the decreased mRNA levels of SREBP target genes in
the liver, we found that the protein levels of precursor and
nuclear SREBP1 (Figure 3(a)) and SREBP2 (Figure 3(b)) in
the liver of broiler chickens were decreased (about pSREBP1
28%, nSREBP1 21%; pSREBP2 14%, nSREBP2 24%) in the
clofibrate group compared to the control group (𝑃 < 0.05).
3.6. Relative mRNA Levels of INSIG1 and INSIG2 in the Liver.
To study whether the reduced activation of SREBPs by clofi-
brate in the liver of broiler chickens involves upregulation of
INSIGs, we determined mRNA levels of INSIG1 and INSIG2
in the liver. As demonstrated in Figure 4, the relative mRNA
level of INSIG2 in the liver was about 40% greater in the
clofibrate group than in the control group (𝑃 < 0.05), whereas







































































































Figure 3: Protein levels relative to control of precursors and nuclear forms of SREBP1 and SREBP2 in the liver of broiler chickens fed diets
without (control) or with 0.1% clofibrate for 4 weeks. Representative immunoblots specific to precursors and nuclear SREBP1 (a) and SREBP2
(b) and 𝛽-actin as internal control are shown for one pool per group; immunoblots for the other pools revealed similar results. Values are
means ± SEM, 𝑛 = 3 pools/group with each pool representing 3 animals.
3.7. Relative mRNA and Protein Level of LXR𝛼 in the Liver. In
order to explain the reduced expression of SREBP target genes
in the liver of clofibrate-treated broiler chickens, we finally
determined mRNA and nuclear protein levels of LXR𝛼 in the
liver.We observed that bothmRNA (Figure 5(a)) and nuclear
protein levels of LXR𝛼 (Figure 5(b)) in the liver of broiler
chickens were decreased (about 25% and 35%, resp.) in the
clofibrate group compared to the control group (𝑃 < 0.05).
4. Discussion
In the present study we investigated the regulatory mecha-
nism of the triglyceride- and cholesterol-lowering effect of
the PPAR𝛼 agonist clofibrate in broiler chickens, a species
in which the liver is the predominant site of lipogenesis. We
found that clofibrate did not influence the final body weight
and feed conversion ratio between the control and treatment
groups but lowered the concentrations of triglyceride and
cholesterol in the liver of broiler chickens. We also observed
that mRNA and protein levels of LXR𝛼 and mRNA and both
precursor and nuclear protein levels of SREBP1c and SREBP2,
which are the master regulators of genes involved in lipid
synthesis and uptake, aswell as the expression of SREBP1c and
SREBP2 target genes (FASN, GPAM, HMGCR, and LDLR)
were clearly decreased in treatment group.The similar effects
were found in the liver of rats and rat liver cells by treatment
with PPAR𝛼 activators [9–11]. Numerous studies reported
that SREBPs were regulated at multiple levels, namely, at the
























Figure 4: mRNA level relative to control of INSIG1 and INSIG2 in
the liver of broiler chickens fed diets without (control) or with 0.1%
clofibrate for 4 weeks. Values are means ± SEM, 𝑛 = 24/group.
controls cholesterolgenic genes primarily by affecting pro-
teolytic processing with only minor changes in the level
of mRNA, whereas SREBP1c regulates lipogenic enzymes
mainly by self-regulating its own transcription level due to the
presence of SRE in promoter of SREBF1, or rather by changing
mRNA level of SREBF1 inhibiting the proteolytic activity to
cleave SREBP1c precursor into its nuclear form, indicating
that SREBP1 is regulated in a different fashion than SREBP2
[35–37]. The present study demonstrated that the abundance



















































Figure 5: mRNA and protein level relative to control of LXR𝛼 in the liver of broiler chickens fed diets without (control) or with 0.1% clofibrate
for 4 weeks. (a) Bars represent means ± SEM (𝑛 = 24/group) and are expressed mRNA level relative to the control group. (b) Representative
immunoblot specific to nuclear LXR𝛼 and 𝛽-actin as internal control is shown for one pool per group; immunoblots for the other pools
revealed similar results. Values are means ± SEM, 𝑛 = 3 pools/group with each pool representing 3 animals.
form were decreased in a proportional way by the clofibrate
treatment. This indicates that the decrease in lipogenesis
observed is mostly due to a decrease in the overall tran-
scription of SREBF1. Peterson et al. [34] demonstrated that a
short term (48 h) treatment with trans-10, cis-12 CLA reduces
lipid synthesis in bovine mammary epithelial cells through
inhibition of proteolytic activation of SREBP1 and subsequent
reduction in transcriptional activation of lipogenic genes. A
longer-term treatment (4 weeks) with clofibrate in present
studywould possibly lead to a reduced abundance of SREBP1c
mRNA and precursor protein. However, the mechanism by
how the clofibrate lower SREBF1 mRNA levels in liver of
broiler chickens remains to be explored. Taken together, these
findings suggest that SREBP1c represses lipogenic genes such
as FASN andGPTM and inhibits lipogenesis and lipid uptake
in the liver of broiler chickens by a mechanism involving
reduction of SREBP1 transcription and activation contribut-
ing to lower lipids levels in liver of broiler chickens.
Despite reporting in earlier studies that PPAR𝛼 activation
is accompanied by an inhibition of SREBP-dependent gene
expression, it is currently unknown how PPAR𝛼 activation
mediates this effect. It has been identified that mouse and
human SREBF1c gene is a direct LXR𝛼 target gene with
two LXR response elements (LXREs) found in the SREBF1c
promoter region [38–40].This indicates that the expression of
SREBF1c is regulated by LXR𝛼. LXR𝛼, like PPAR𝛼, functions
usually as obligate heterodimer with retinoid X receptor
(RXR𝛼)which regulates the transcription of their target genes
by binding to LXRE of target promoter. A recent study has
demonstrated that overexpression of PPAR𝛼 and treatment
with PPAR𝛼 agonist both enhance binding of PPAR𝛼 to
RXR𝛼 and decrease the amount of LXR/RXR heterodimers,
leading to suppression of LXR𝛼 ligand-activated SREBF1c
expression in rat primary hepatocyte cultures andmouse liver
[18]. This suggests that the mechanism for PPAR𝛼 inhibition
of LXR𝛼-mediated transcriptional activity of SREBF1c could
be at RXR competition between PPAR𝛼 and LXR𝛼. Besides,
PPAR𝛼 can heterodimerizewith LXR𝛼 and results in interfer-
ence of LXR/RXR formation and inhibition of SREBF1c pro-
moter activation [41].Thus, our results suggest that decreased
expression of nuclear LXR𝛼 by clofibrate may contribute
to the lipid-lowering effect of PPAR𝛼 by inhibiting LXR-
dependent SREBF1c transcription in the liver of broiler chick-
ens. However, more detailed promoter studies, for example,
using reporter gene or gel-shift assays, will be needed to
determine if the broiler SREBF1c gene is also a target gene of
LXR𝛼.
Studies reported that SREBP2 controls cholesterol syn-
thesis through cleavage of the membrane-bound precursor
protein to liberate its nuclear active form in the nucleus [36,
37]. Convincing evidence has been provided that PPAR𝛼 acti-
vator WY 14,643, a potent PPAR𝛼 ligand, decreases hepatic
cholesterol concentration inwild typemice, but not in PPAR𝛼
null mice, by alteration in membrane fatty acid composition
that influenced SREBP activation, suggesting that PPAR𝛼
plays an important role to control SREBP2 activity and hep-
atic cholesterol biosynthesis [42]. The present study demon-
strate that the nuclear protein level of SREBP2 ismarkedly less
than precursor protein level by the clofibrate treatment indi-
cating that SREBP2 controls cholesterol synthesis at the cleav-
age system. In contrast to our results the studies reported that
the expression levels of mRNAs and proteins which involved
in cholesterol biosynthesis were increased after WY 14,643
treatment in the liver of wild type mice, but in fact these
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increases seem not to be associated with hepatic de novo
cholesterologenesis; thus, the present study supported the
observations in mice that PPAR𝛼 agonist treatment does not
lead to a stimulation of the hepatic cholesterol synthesis but
rather decreases it [42, 43]. We have also found in the present
study that clofibrate slightly increased hepatic expression of
INSIG1 and significantly that of INSIG2. In line with this,
recent studies revealed that transcription of INSIG1 in rat
liver and INSIG1 and INSIG2 in rat Fao cells was increased by
treatment with PPAR𝛼 agonistWY-14,643 [10]. Similarly, rats
administered an oxidized dietary fat, like frying oil, which is
known to cause strong activation of hepatic PPAR𝛼 [44], were
found to have increased mRNA levels of INSIG1 and INSIG2
in the liver [9]. Both, INSIG1 and INSIG2 are responsible for
retaining the precursor forms of SREBP1 and SREBP2 within
the endoplasmic reticulum thereby inhibiting the proteolytic
processing of SREBPs in the Golgi [45, 46]. Thus, it can be
proposed that the upregulation of INSIGs by clofibrate causes
an inhibition of the release of the SCAP-SREBP complex from
INSIGs and its translocation to the Golgi, where proteolytic
processing (activation) of SREBPs occurs. PPAR𝛼 and other
PPAR isoforms (PPAR𝛾, PPAR𝛿/𝛽) are known to stimulate
transcription of target genes through binding as a complex
with retinoic acid-X receptor to specific DNA sequences,
called PPREs, in the regulatory region of target genes [8, 47,
48]. Interestingly, it has been recently shown that the human
INSIG1 gene contains a functional PPRE, which is regulated
by both, PPAR𝛿 [49] andPPAR𝛾 [50].Moreover, it was shown
that adenovirus induced-overexpression of PPAR𝛿 causes
induction of INSIG1 and suppression of SREBP1 activation
and lipogenesis in the liver of obese diabetic mice [49]
indicating that upregulation of INSIGs by clofibrate may
also explain inhibition of SREBP-dependent gene expression
and lipogenesis in the liver of broiler chickens. Although it
remains to be shown whether the chicken genes encoding
INSIG1 or INSIG2 are also regulated by PPAR𝛼, it is well-
known that the functional PPREs of many PPAR target genes
are regulated by all three PPAR isotypes.The CPT1A gene, for
instance, which was used as an indicator to assess activation
of PPAR𝛼 by clofibrate in the present study, is known to
possess a functional PPRE in its promoter which is bound
by PPAR𝛼, PPAR𝛾, and PPAR𝛿/𝛽 target genes in broilers.
However, future studies using reporter gene and gel-shift
assays have to clarify whether or not the genes encoding
INSIGs are PPAR target genes.
In conclusion, the results of the present study demon-
strated that PPAR𝛼 agonist clofibrate lowers the triglyceride
concentration in broiler liver by reducing transcription and
activation of SREBP1 and by repressing LXR𝛼-mediated tran-
scriptional activity of SREBP1, which subsequently reduced
lipogenic gene expression of FASN and GPTM, whereas
PPAR𝛼 agonist clofibrate decreases cholesterol concentration
in broiler liver by upregulating the expression of INSIG2
that inhibits proteolytic cleavage and activation of SREBP2,
subsequently reducing SREBP2-dependent gene expression
of LDLR and HMGAR, thereby resulting in the decrease of
synthesis capacity of triglyceride and cholesterol in the broiler
liver.
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